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Abstract: Drug-induced liver injury (DILI) is a potentially fatal adverse event and a leading cause
for pre- and post-marketing drug withdrawal. Several multinational DILI initiatives have now
recommended a panel of protein and microRNA (miRNA) biomarkers that can detect early liver injury
and inform about mechanistic basis. This manuscript describes the development of seqCOMBO,
a unique combo-multiplexed assay which combines the dynamic chemical labelling approach and
an antibody-dependant method on the Luminex MAGPIX system. SeqCOMBO enables a versatile
multiplexing platform to perform qualitative and quantitative analysis of proteins and miRNAs
in patient serum samples simultaneously. To the best of our knowledge, this is the first method to
profile protein and miRNA biomarkers to diagnose DILI in a single-step assay.
Keywords: dynamic chemical labelling (DCL); drug-induced liver injury (DILI); miRNA-122; Luminex
MAGPIX; liquid biopsy; antibody-dependant method
1. Introduction
Adverse drug reactions (ADRs) are a significant concern for patients, healthcare pro-
fessionals and the pharmaceutical industry, with an estimated annual cost to the EU of
EUR 79 billion [1]. Drug-induced liver injury (DILI) is the second-most common ADR [2]
and a leading cause of acute liver failure (ALF) in the western world [3]. ALF is a life-
threatening condition, and identifying patients at risk for ALF is a priority task. DILI
incidence depends on the drug itself and host/patient-specific factors such as sex, ethnicity
and genetic polymorphism in the detoxification of drugs [4]. For instance, for the antibi-
otic amoxicillin-clavulanate, approximately 1 out of 2300 patients will develop DILI [5].
Additionally, DILI is one of the leading causes of drug attrition throughout all stages of
the drug discovery process. In early development, 50% of all pre-clinical candidate drugs
display effects upon the liver at supra-therapeutic doses. Over the last 50 years, DILI was
responsible for 18% of all medicines retracted post-marketing (the main reason for the drug
withdrawals) [6,7]. From 1997 to 2016, in the EU and USA, eight drugs were withdrawn
due to DILI-related incidents, which have led to liver transplants and deaths [8]. The
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interpretation of laboratory findings of suspected hepatotoxicity cases in clinical trials is
complex, as increased levels of hepatic enzymes are not necessarily a signal of impending
DILI, but may be due to hepatic adaption, other underlying liver diseases or non-hepatic
sources of the enzymes [9]. Therefore, a method capable of predicting and clearly diagnos-
ing drug-induced hepatotoxicity before market authorization, as well as to support the
clinical management of DILI, would be highly desirable.
To date, DILI assessment and drug toxicity evaluation has relied on the analysis of
a panel of serum biomarkers such as alanine aminotransferase (ALT), aspartate amino-
transferase (AST), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), glutamyl
transpeptidase (GT), albumin and bilirubin [10]. This panel is commonly used in DILI
assessment but has limitations [11]. None of the markers offers true mechanistic insight
into the basis of DILI, and some are less liver-specific or detected late after DILI onset, when
liver injury is already advanced, limiting the potential treatment options [9]. Therefore,
there is an urgent need for better DILI biomarkers to improve risk assessment and patient
management.
The discovery of microRNAs (miRNAs) as a new class of gene expression regulators
has triggered an explosion of research, particularly the measurement of miRNAs in various
body fluids, valuable as biomarkers for many human diseases [11,12]. The properties
of miRNA-based biomarkers, such as tissue specificity and high stability and sensitivity,
suggest they could be used as novel, minimally invasive and stable DILI biomarkers. Over
the past several years, many animal and clinical studies have been published, routinely
showing that miRNAs have an advantage over conventional biomarkers for DILI [13,14].
They are relatively stable [15], can be highly liver-specific [16], are significantly altered
in pathologic states [12], are readily detectable in easily accessible bodily fluids [17–20]
and are strictly conserved between species [21]. In particular, liver-specific miRNA-122
(miR-122) is a key liver miRNA, involved in various processes of liver development,
differentiation, metabolism and stress responses [7,20]. Compared with conventional
hepatotoxic markers, circulating miR-122 can effectively and consistently distinguish
intrahepatic from extrahepatic damage with higher sensitivity and specificity. Thus, miR-
122 is expected to be a valuable pre-clinical and clinical biomarker of DILI [22].
Several international initiatives such as the Safer and Faster Evidence-based Trans-
lation (SAFE-T) consortium or, more recently, TransBioLine and the Pro-Euro DILI NET-
WORK have been seeking and validating DILI biomarkers as means to better diagnose
DILI [23,24]. A recent letter of support from the EMA [25] established that the lack of
sensitive and specific assays to diagnose, predict and monitor idiosyncratic DILI remains
a severe hurdle in drug development. All the scientific evidence points out that an inno-
vative combination of biomarkers combining proteins and miRNAs would probably be
optimal to clearly identify DILI and predict the course of the liver injury, and may help in
assigning causality.
To analyse proteins and miRNAs using conventional technologies, the clinical sample
has to: (i) be split in two; (ii) use the 1st split for testing proteins by an antibody-dependant
method or immunological assay (about 2 h); (iii) use the 2nd split for testing miRNAs
by RT-qPCR (extraction, enrichment of small RNAs, reverse transcription and real-time
amplification—about 5 to 6 h). In 2020, Wang et al. reported a new method to interrogate
protein and miRNA spike-ins [26]. However, and to the best of our knowledge, a simultane-
ous detection of both molecules from clinical samples has not been yet reported. This aspect
is critical as endogenous miRNAs are found in circulation within vesicles and/or bound to
argonaute (AGO) proteins while spike-in miRNAs are free molecules. Hence, the protocol
needed to simultaneously detect natural miRNAs and proteins is very different from the
protocol used to detect spike-in miRNAs and proteins. With the advances made by our
team with dynamic chemical labelling (DCL) technology for the direct detection of nucleic
acids, the deliverable of simultaneous detection of protein and miRNA in clinical samples
is now possible. The DCL approach [17–20,27–33] is particularly well suited to deliver
consistent and reliable quantitative readings of miRNAs in clinical samples when merged
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with bead-based systems. By simplifying the workflow, especially removing extraction,
isolation and amplification steps, DCL was able to direct detect miRNAs in enzyme-linked
immunosorbent assay (ELISA)-type format without affecting protein co-analytes, overcom-
ing the current limitation issues that inhibit the development of simultaneous detection of
proteins and miRNAs with high specificity and accuracy.
In this study, the DCL approach and an antibody-dependant method were combined
with the Luminex MAGPIX system to deliver the simultaneous detection of DILI-related
protein and miRNA with sensitivity and high specificity. This combined system, named
“seqCOMBO”, was applied to profile levels of liver-type arginase 1 (ARG1) and miR-122 in
a serum sample from a DILI patient. Serum samples from no DILI patient were used as
controls. ARG1 is a highly abundant protein found in liver cytosol, used to improve the
sensitivity of ALT to detect liver injury [34]. Among all protein biomarkers, ARG1 was used
for this study since it is part of the commercially available MILIPLEX MAP Human Liver
Injury Magnetic Bead Panel. As stated above, multiple studies have already demonstrated
the sensitivity and specificity of miR-122 as a valuable circulating biomarker of liver injury,
including DILI [7], hepatitis C [35] and ethanol consumption [36].
2. Materials and Methods
2.1. Materials
MILLIPLEX MAP reagents for analysing ARG1 were purchased from Merck (MILI-
PLEX MAP Human Liver Injury Magnetic Bead Panel—Toxicity Multiplex Assay, Cat #
HLINJMAG-75K) and were used as received. The MILIPLEX MAP kit includes anti-ARG1
beads with colour region 26 [37], assay buffer and detection antibody. Luminex MagPlex®
carboxylated beads from colour region 12 were purchased from Luminex Corporation
(1.25 × 107/mL).
The DGL 122 abasic PNA probe (Table S1), aldehyde-modified biotinylated cytosine
nucleobase (SMART-C biotin; Figure S1) and buffers (inluding the Stabiltech lysis buffer)
for interrogating miR-122 were provided by DESTINA Genomica S.L. (Section S1). Luminex
MagPlex® carboxylated beads from colour region 12 [37] were functionalised with DGL
122 abasic PNA, using the protocol optimised by DESTINA Genomica S.L. (Section S2), to
generate the DGL-122 beads. Synthetic mimic miR-122 oligomer was purchased from Inte-
grated DNA Technologies (Table S1). Concentrations of DNA solutions were determined
using a ThermoFisher NanoDrop1000 spectrophotometer. Streptavidin-R-Phycoerythrin
(SA-PE, 1 mg/mL) was purchased from Moss Biotech Inc. Chemicals for bead coupling
were purchased from Sigma-Aldrich, and 96-well plates were purchased from Thermo
Fisher (Cat. # 249570). Incubations and reactions were carried out in a microplate orbital
shaker (VWR Micro Plate Shaker, Cat. # 12620-926).
2.2. Clinical Samples
An adult DILI patient was recruited, fulfilling the study inclusion and exclusion
criteria [38]. A no DILI patient was included in the study as control. Full informed consent
was obtained from the patient, and ethical approval was given by the South East Scotland
Research Ethics Committee and the East of Scotland Research Ethics Committee, via the
South East Scotland Human Bioresource. Blood samples were taken at first presentation
to hospital and centrifuged immediately at 11,000× g for 15 min at 4 ◦C. Then, serum
was separated into aliquots and stored at −80 ◦C. Just prior to analysis, serum aliquots
were thawed at room temperature for approximately 30 min. The primary endpoint for
the study was acute liver injury, pre-defined as a peak hospital stay serum ALT activity
greater than 100 U/L. ALT activity in clinical samples were analysed elsewhere [22], using
a commercial serum ALT kit (Alpha Laboratories Ltd., Eastleigh, UK) adapted for use
on either a Cobas Fara or Cobas Mira analyser (Roche Diagnostics Ltd., Welwyn Garden
City, UK). Ct values levels of miR-122 in clinical samples were analysed elsewhere by
RT-qPCR using the normalizer C. elegans miR-39 spike-in [17]. No DILI patient was human
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serum from male AB clotted whole blood and was purchased from Sigma-Aldrich, Cat.
No. H6914-20ML.
2.3. Calibration Curves for ARG1 and miR-122 Assays
Two calibration curves were generated for ARG1 and miR-122 as described below.
2.3.1. Calibration Curve for ARG1 Assay
The calibration curve was generated according to the manufacturer’s instructions for
MILIPLEX MAP. MFI measurements were performed in triplicate as shown in Table S2.
2.3.2. Calibration Curve for miR-122 Assay
Standard solutions were prepared by dissolving varying quantities of synthetic mimic
miR-122 in 24 µL of lysis buffer (see Table S3). Lysis buffer only was used for 0 pM standard.
A volume of 10 µL of serum matrix solution and 1 µL of DGL-122 beads, respectively, were
added to each well containing the standard. This first step, to hybridise the miR-122, was
performed in a 96-well plate using a microplate orbital at 700 rpm for 1 h at 40 ◦C. After
the hybridization, the DGL-122 beads were washed three times with the wash buffer. The
DGL-122 beads were resuspended in 50 µL of assay buffer containing 5 µM SMART-C
biotin and 1 mM sodium cyanoborohydride [17–20,27–33]. The 96-well plate was shaken
at 700 rpm at 40 ◦C for 1 h. The beads were washed three more times and incubated with
70 µL of 2 µg/mL SA-PE for 5 min at 40 ◦C while being shaken at 700 rpm. The beads
were then washed two times with the wash buffer and analysed on the Luminex MAGPIX
system to determine the MFI values. MFI measurements were performed in triplicate as
shown in Table S3.
2.4. ARG1 Singleplex Assay
A volume of 10 µL of serum sample was mixed with 25 µL of assay buffer and 7.5 µL
of anti-ARG1 beads 1:6 diluted from the stock. This first step, to capture the ARG1, was
performed in a 96-well plate using a microplate orbital shaker at 700 rpm for 2 h at 25 ◦C.
After the capturing of ARG1, the anti-ARG1 beads were washed three times with the wash
buffer. The anti-ARG1 beads were resuspended in 50 µL of detection antibody diluted 1:2
with assay buffer. The 96-well plate was shaken at 700 rpm at 25 ◦C for 1 h. The beads
were washed three more times and incubated with 70 µL of 2 µg/mL SA-PE for 5 min
at 40 ◦C while being shaken at 700 rpm. The beads were then washed two times with
the wash buffer and analysed on the Luminex MAGPIX system to determine the mean of
fluorescence intensity (MFI) values. MFI measurements were performed in triplicate as
shown in Table S4.
2.5. miR-122 Singleplex Assay
A volume of 10 µL of serum sample was mixed with 30 µL of assay buffer and 80 µL
of lysis buffer (Stabiltech buffer) [17,30] containing DGL-122 beads functionalized with
DGL-122. This first step, to hybridise the miR-122, was performed in a 96-well plate using
a microplate orbital shaker at 700 rpm for 1 h at 40 ◦C. SMART-C biotin incorporation and
SA-PE labelling were carried out as described in Section 2.3.2. MFI measurements were
performed in triplicate as shown in Table S4.
2.6. SeqCOMBO Assay
A volume of 10 µL of serum sample was mixed with 25 µL of assay buffer and 7.5 µL
of anti-ARG1 beads 1:6 diluted from the stock. This first step allows capturing the ARG1
and was performed in a 96-well plate using a microplate orbital shaker at 700 rpm for 2 h
at 25 ◦C. After the capturing, the supernatant was removed and kept for the subsequent
miR-122 hybridization. The anti-ARG1 beads’ pellet was washed three times with the
wash buffer, resuspended in 100 µL of assay buffer and reserved at 4 ◦C. The supernatant
containing miR-122 was treated by adding 80 µL of Stabiltech buffer containing 1250 DGL-
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122 beads. The hybridization of miR-122 was performed at 700 rpm for 1 h at 40 ◦C. After
the hybridization, the DGL-122 beads were washed three times with the wash buffer. The
DGL-122 beads were resuspended in 100 µL of wash buffer and merged with the reserved
100 µL solution containing anti-ARG1 beads. Once both set of beads were mixed, the
supernatant was removed and resuspended in 25 µL of detection antibody and 25 µL of
assay buffer containing 5 µM of SMART-C biotin and 1 mM sodium cyanoborohydride.
The 96-well plate was shaken at 700 rpm at 40 ◦C for 1 h. The beads were washed three
times and incubated with 70 µL of 2 µg/mL SA-PE for 5 min at 40 ◦C while being shaken
at 700 rpm. The beads were then washed two times with the wash buffer and analysed
on the Luminex MAGPIX system to determine the MFI values. MFI measurements were
performed in triplicate as shown in Table S4.
3. Results and Discussion
3.1. Singleplex Assay—Analysis of ARG1 and miR-122
DILI and no DILI patient samples were tested individually to analyse ARG1 and
miR-122 levels. The Ct value levels of miR-122 in DILI and no DILI samples were analysed
elsewhere [17]. The average Ct signals obtained for the DILI sample was 19.5 ± 0.03 (data
refer to the canonical miR-122). The individual analysis was carried out by the workflows
illustrated in Figure 1 and as described in Sections 2.4 and 2.5. The MILIPLEX assay for the
detection of ARG1 and the DCL method for miR-122 require, respectively, 3 h 15 min and
2 h 15 min. Both workflows consist of five main steps.
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Figure 1. Singl plex workflows. (a) Analysis of ARG1: Step 1 —anti-ARG1 beads are ad ed to the
sample; Step 2a—anti-ARG1 beads capture ARG1; Step 3a—detection antibody is added, recognizing
the captured ; t s are labelled using SA-PE; Step 5a—beads are read out by
measuring the values of MFI into the Luminex MAGPIX system. (b) Analysis of miR-122: Step
1b—DGL-122 beads are added to the sample; Step 2b—DGL-122 beads hybridise miR-122; Step
3b—DCL reagents are added into the solution to incorporate the SMART-C biotin; Step 4b—beads are
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The two assays enabled us to profile levels of ARG1 and miR-122 in a DILI patient. As
reported in Table S4, the patient with DILI presented high levels of both ARG1 and miR-122,
while, and as expected, the no DILI patient did not show significant levels of either ARG1
or miR-122. ARG1 and miR-122 levels were quantified using the two calibration curves
generated with the data reported in Tables S2 and S3, respectively. Levels of ARG1 and
miR-122 were extrapolated and reported in Table S4 and shown in Figure 2.
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3.2. SeqCOMBO Assay—Analysis of ARG1 and miR-122 Simultaneously
The two individual assays described in Figure 1a,b were combined delivering the
seqCOMBO to profile at the same time the levels of ARG1 and miR-122 in the serum
sample of a DILI patient. As shown in Figure 3, the seqCOMBO workflow consists of nine
main steps.
The seqCOMBO enables profiling levels of ARG1 and miR-122 in the DILI patient. As
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4. Conclusions
To date, it has not been possible to analyse proteins and nucleic acids of clinical rel-
evance into a single assay on the same analytical platform. This is due to the technical
peculiarities of handling RNA without affecting protein analytes. miRNAs are present in
body fluids contained in complexes such as lipidic membranes and/or AGO proteins. To
liberate the miRNA targets, current technologies use lysis buffers containing proteases
to release the target from complexes in order to be interrogated [39]. While treatments
with lysis buffers enable the release of miRNAs, this can impact the downstream protein
analysis and characterization. Prompted by these current analytical limitations, our group
developed seqCOMBO, a new method to overcome the inability of current technology to
analyse miRNAs without affecting proteins. In seqCOMBO, our DCL transformative tech-
nology to interrogate miRNAs [17–20,27–33] was combined with an antibody-dependant
method on the Luminex MAGPIX system.
SeqCOMBO consists of a sequential interrogation of analytes, including: (i) capturing
the protein biomarker first; (ii) centrifuging and reserving the pellet that contains the
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protein; (iii) treating the remaining supernatant with the Stabiltech buffer to release miRNA
(Figure 3). Once the miRNA is released and captured, protein and miRNA beads are mixed
again to finalise the process and read the results. SeqCOMBO is able to determine the
levels of DILI-related protein and miRNA simultaneously. SeqCOMBO was validated
using clinical samples from a patient with liver injury, determining the levels of ARG1 and
miR-122 successfully. When MFI values between both singleplex and seqCOMBO were
compared, no signal differences were observed, thus demonstrating the high compatibility
of the antibody-dependant method with DCL reagents on the Luminex system.
Embedded in its combined technologies, seqCOMBO is a radical diagnostic approach
that shows the practicality of using the same patient sample to analyse both protein and
nucleic acid biomarkers of clinical importance. Notwithstanding seqCOMBO’s total focus
on DILI diagnostics, the method developed will clearly find significant new diagnos-
tic opportunities beyond DILI. One example would be viral diseases, where rapid and
accurate identification of proteins and nucleic acids simultaneously will deliver high speci-
ficity/sensitivity assays, well beyond current capabilities. The current Covid-19 pandemic
crisis needs reliable and error-free testing for both genomic RNA and antibodies generated
in infected patients. SeqCOMBO could also prove highly valuable in cancer diagnostics
and monitoring of the disease.
SeqCOMBO shows the way forward to simplified, more cost-effective and robust
multiplex tests in the future, with optimized protein/RNA biomarker combinations.
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